LONGEVERON INC

Explore Longeveron’s 1‑for‑10 reverse split and CFO’s 300k RSU grant, revealing management’s long‑term focus amid a bearish market mood.

Insider buying spikes for Longeveron as executives pile on shares, hinting at internal confidence amid rising stock and clinical‑stage buzz.

Discover how Longeveron’s insider buying and selling signals investor confidence amid a 57% stock drop and promising Phase 2a results.

Insider RSU and option grants by Longeveron’s chief scientist signal long‑term confidence in its aging‑therapy pipeline, offering a bullish hint amid volatile shares.

Lehr Paul T’s recent Longeveron share sale signals a gradual insider divestment; investors should weigh this cautious shift against the company’s speculative fundamentals and upcoming clinical milestones.

Insider sales by Longeveron’s top execs signal a strategic shift—watch for funding or partnership moves that could change the stock’s trajectory.

CEO Willard H. boosts Longeveron stake by 147%—buying 200k shares while selling 105k—to signal confidence amid a 152% social‑media surge, but clinical milestones still dictate long‑term value.